Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
80.86USD
8:20pm BST
80.86USD
8:20pm BST
Change (% chg)
$-1.09 (-1.33%)
$-1.09 (-1.33%)
Prev Close
$81.95
$81.95
Open
$81.27
$81.27
Day's High
$82.40
$82.40
Day's Low
$79.36
$79.36
Volume
124,973
124,973
Avg. Vol
295,896
295,896
52-wk High
$153.80
$153.80
52-wk Low
$78.93
$78.93
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 29.91 | -1.627 |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 | |
| FY 2016 | Dec '16 | 17.45 | -1.316 |
| Sep '16 | 13.65 | -1.214 | |
| Jun '16 | 8.71 | -1.054 | |
| Mar '16 | 7.34 | -1.208 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 13 | 25.87 | 68.41 | 3.80 | 57.38 |
| Quarter Ending Mar-19 | 7 | 32.23 | 101.56 | 7.50 | -- |
| Year Ending Dec-18 | 17 | 99.93 | 157.71 | 55.60 | 124.97 |
| Year Ending Dec-19 | 18 | 202.13 | 518.29 | 83.60 | 334.91 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 13 | -2.14 | -1.73 | -2.72 | -1.27 |
| Quarter Ending Mar-19 | 7 | -2.00 | -1.25 | -2.41 | -- |
| Year Ending Dec-18 | 15 | -7.18 | -6.62 | -7.70 | -5.30 |
| Year Ending Dec-19 | 17 | -7.39 | -5.73 | -9.65 | -3.42 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 85.91 | 32.75 | |
| P/E High - Last 5 Yrs. | -- | 301.66 | 45.42 | |
| P/E Low - Last 5 Yrs. | -- | 92.42 | 24.25 | |
| Beta | 2.97 | 0.93 | 0.89 | |
| Price to Sales (TTM) | 170.48 | 115.65 | 5.74 | |
| Price to Book (MRQ) | 10.02 | 15.58 | 5.00 | |
| Price to Tangible Book (MRQ) | 10.02 | 14.67 | 6.57 | |
| Price to Cash Flow (TTM) | -- | 73.07 | 23.28 | |
| % Owned Institutions | 96.38 | 14.71 | 2.26 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.35 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.25 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 1.73 | 5.24 | |
| Payout Ratio(TTM) | -- | 16.54 | 43.77 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 413.24 | 8.00 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 79.21 | 5.62 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 32.28 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 27.96 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 40.04 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 40.58 | 15.33 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.91 | 2.22 |
| Current Ratio (MRQ) | 8.84 | 5.19 | 3.03 |
| LT Debt to Equity (MRQ) | 13.36 | 35.49 | 12.55 |
| Total Debt to Equity (MRQ) | 13.36 | 37.32 | 16.89 |
| Interest Coverage (TTM) | -- | -102.94 | 32.71 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 38.99 | 54.34 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.37 | 52.13 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -605.43 | 10.68 | |
| Operating Margin (TTM) | -680.48 | -764.71 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -626.59 | 6.11 | |
| Pre-Tax Margin (TTM) | -670.81 | -738.48 | 5.20 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -632.35 | 6.52 | |
| Net Profit Margin (TTM) | -670.81 | -739.84 | 1.49 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -635.37 | 2.79 | |
| Effective Tax Rate (TTM) | -- | 23.37 | 23.12 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.66 | 23.98 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 23,344,613 | 859,711,668 | |
| Net Income/Employee (TTM) | -861,313 | 3,159,253 | 101,129,378 | |
| Receivable Turnover (TTM) | 5.30 | 20.76 | 5.87 | |
| Inventory Turnover (TTM) | -- | 2.46 | 3.41 | |
| Asset Turnover (TTM) | 0.05 | 0.41 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | -0.24 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | 3.46 | 12.40 | |
| Return on Investment (TTM) | -33.58 | 1.70 | 14.60 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 2.51 | 16.13 | |
| Return on Equity (TTM) | -39.86 | 3.17 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 3.37 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 52 |
| 13 Week | 45.87 | 38.77 | 99 | 64 |
| 26 Week | 152.83 | 133.61 | 99 | 77 |
| 52 Week | 238.72 | 187.09 | 99 | 50 |
| YTD | 227.59 | 187.69 | 99 | 59 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- With Hemlibra, Roche seeks to break into tight hemophilia circle
- With Hemlibra, Roche seeks to break into tight hemophilia circle
- FOCUS-With Hemlibra, Roche seeks to break into tight hemophilia circle
Institutional Holders
| % Shares Owned: | 92.17% |
| # of Holders: | 455 |
| Total Shares Held: | 92,785,345 |
| 3 Mo. Net Change: | 459,286 |
| # New Positions: | 4 |
| # Closed Positions: | 3 |
| # Increased Positions: | 28 |
| # Reduced Positions: | 16 |
| # Net Buyers: | 12 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.